Marker Therapeutics, Inc.

Category: Press Releases

TapImmune to Present at 2018 NYC Oncology Investor Conference

TapImmune President & CEO, Peter Hoang, will be giving a company presentation at the 2018 NYC Oncology Investor Conference on May 9th at 3:00pm ET.
Read More

TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference

TapImmune President & CEO, Peter Hoang, will be participating in a panel discussion and give a company presentation at the 2018 Disruptive Growth & Healthcare Conference on May 9th.
Read More

TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update

Please join us for our fourth quarterly call and year end update of 2017 today, April 5, 2018, 4:30pm ET.
Read More

TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast

Please join us for our fourth quarterly call and year end update of 2017 on April 5, 2018 at 4:30pm.
Read More

TapImmune to Present at The MicroCap Conference

TapImmune President and CEO, Peter Hoang, to present at 2018 The Microcap Conference.
Read More

TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research

The publication of clinical data from a Phase 1 trial of TPIV200, the company’s multi-epitope T-cell vaccine targeting Folate Receptor Alpha in patients with ovarian and breast cancer will be available online today.
Read More

TapImmune to Present at Two Upcoming Investor Conferences

TapImmune President & CEO, Peter Hoang, will be participating in two conferences next week.
Read More

TapImmune to Participate in Two Upcoming Investor Conferences

TapImmune President & CEO, Peter Hoang, will be participating in two conferences in the upcoming weeks.
Read More

TapImmune to Present at Biotech Showcase™ 2018

TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.
Read More

TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense

“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.
Read More